There are currently 544 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
NCT05988658
Recruiting
The study's objective is to evaluate the additive value of renal biomarkers (from blood and urine) for identifying individuals at high risk for severe acute kidney injury (AKI) above that of a novel natural language processing (NLP)-based AKI risk algorithm. The risk algorithm is based on electronic health records (EHR) data (labs, vitals, clinical notes, and test reports). Patients will enroll at the University of Chicago Medical Center and the University of Wisconsin Hospital, where the risk s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: University of Wisconsin Hospital, Madison, Wisconsin
Conditions: Acute Kidney Injury, Biomarkers
Register for Updates
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
NCT03455725
Recruiting
Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/05/2024
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Refractory Angina, Chronic Myocardial Ischemia
Register for Updates
Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction
NCT05860257
Recruiting
Adolescence is a developmental period of significant risk for anxiety, depressive symptoms, and suicidality, and the investigators propose to target key peer-based risk and protective factors using Cooperative Learning (CL). CL is a small-group instructional approach that can enhance peer relations and reduce peer-related risks, as well as promote academic engagement and achievement and reduce racial disparities. CL will be delivered with the aid of technology that automates the design and deliv... Read More
Gender:
ALL
Ages:
Between 14 years and 65 years
Trial Updated:
08/05/2024
Locations: U of Wisconsin, Madison, Wisconsin
Conditions: Anxiety Depression, Suicidal Ideation
Register for Updates
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
NCT04295863
Recruiting
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: SSM Health Cancer Care, Madison, Wisconsin
Conditions: Metastatic Cancer
Register for Updates
TRAQinform Assessment of Immunotherapy Response
NCT05819255
Recruiting
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Melanoma
Register for Updates
ACCEL Absorbable Hemostat
NCT04728087
Recruiting
The ACCEL® Absorbable Hemostat Powder Clinical IDE Trial is designed as a prospective, multi-center, randomized, non-inferiority, controlled pivotal clinical trial to evaluate the safety and efficacy of the ACCEL® Absorbable Hemostat Powder as compared to gelatin sponge, for achieving hemostasis in subjects undergoing cardiovascular, liver, or soft tissue surgery, when control of oozing to moderate bleeding by standard surgical techniques is ineffective and/or impractical.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/15/2024
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Hemostasis
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: William S Middleton VA Medical Center, Madison, Wisconsin +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Madison, Wisconsin
Conditions: Neoplasms
Register for Updates
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/15/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839
Recruiting
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Solid Tumor, Adult
Register for Updates
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Register for Updates